Salute e Benessere
Cell Based Assays Market worth US$27.55 billion by 2030 with 9.1% CAGR | MarketsandMarkets™
in 2024, pharmaceutical & biopharmaceutical companies led the cell-based assays market. This growth is primarily driven by the increasing demand for drug discovery and development, particularly due to the rising prevalence of cancer. The growing number of research & development activities aimed at creating new pharmaceutical and biotech drugs and therapies is expected to further propel segmental growth. Additionally, a heightened focus on personalized medicine is anticipated to contribute to the segment's expansion. Moreover, increasing investments and funding for cell-based research are expected to promote further growth in the coming years.
the cell-based assays market is divided into six major regions: North America , Europe , Asia Pacific , Latin America , the Middle East , and Africa . The Asia Pacific region is expected to experience the fastest growth in this market, driven by a heightened focus on developing cell-based therapies, substantial government investments and funding for research and development, and a rapidly expanding healthcare sector. Additionally, the modernization of healthcare infrastructure and the increasing adoption of advanced technologies for research and clinical applications are anticipated to further support the growth of cell-based assays in the Asia Pacific region.
The key players in the cell-based assays market include BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA ( Germany ), Agilent Technologies, Inc. (US), Lonza ( Switzerland ), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG ( Germany ), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific ( Luxembourg ), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. ( Japan ), Intertek Group Plc (UK), BICO ( Sweden ), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH ( Germany ), Hanugen Therapeutics ( India ), Altogen Labs (US), and BioAgilytix (US).
is a leading provider of solutions and services for research, biotechnology, and pharmaceutical drug development and production in the global life sciences industry. The company offers tools, services, and digital platforms to empower researchers in a wide range of fields. The company has a strong customer base across North America , Europe , Asia Pacific , Latin America , and the Middle East & Africa through a combination of direct sales teams, distributors, and wholesalers. Additionally, the company continues to focus on organic and inorganic growth strategies such as product launches, agreements, acquisitions, expansions, and collaborations.
is a leading innovator in life sciences and diagnostics. It offers a wide range of products and services for medical, industrial, and commercial applications and has a robust presence in North America , Europe , Asia , and Latin America . The company also focuses on forming strategic alliances to strengthen its global footprint. For example, in October 2023 , Danaher Corporation's Beckman Coulter Life Sciences partnered with 10x Genomics to enhance automation solutions for single-cell assay workflows. Additionally, Danaher is committed to expanding its facilities to grow its business. In May 2022 , Cytiva announced the opening of a new manufacturing facility in Grens, Switzerland . This site will produce single-use kits for the Sepax and Sefia cell processing systems and consumables for the Xuri cell expansion systems.
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, , and . With a , we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cell-based-assays-market-worth-us27-55-billion-by-2030-with-9-1-cagr--marketsandmarkets-302433182.html